title: Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
abstract: OBJECTIVE
  To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC).
  
  
  METHODS
  Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT.
  
  
  RESULTS
  From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1-2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%).
  
  
  CONCLUSIONS
  The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC.
  
  
  CONCLUSIONS
  The largest series of this association.
authors: 1 Radiotherapy Department, Institut Curie, Paris, France.
authors: V
authors: V
authors: Pernin
authors: L
authors: L
authors: Belin
authors: P
authors: P
authors: Cottu
authors: P
authors: P
authors: Bontemps
authors: C
authors: C
authors: Lemanski
authors: B
authors: B
authors: De La Lande
authors: P
authors: P
authors: Baumann
authors: F
authors: F
authors: Missohou
authors: C
authors: C
authors: Levy
authors: K
authors: K
authors: Peignaux
authors: A
authors: A
authors: Reynaud-Bougnoux
authors: F
authors: F
authors: Denis
authors: A
authors: A
authors: Gobillion
authors: M
authors: M
authors: Bollet
authors: N A
authors: NA
authors: Vago
authors: R
authors: R
authors: Dendale
authors: F
authors: F
authors: Campana
authors: A
authors: A
authors: Fourquet
authors: Y M
authors: YM
authors: Kirova
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D005260:Female; D005602:France; D006801:Humans; D008207:Lymphatic Metastasis / Q000532:radiotherapy; D008408:Mastectomy; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references: Int J Radiat Oncol Biol Phys. 1979 Feb;5(2):257-61
references: 110740
references: J Clin Oncol. 2009 Mar 20;27(9):1375-81
references: 19204198
references: Breast Cancer Res Treat. 2013 Dec;142(3):655-65
references: 24253810
references: Lancet Oncol. 2013 Sep;14(10):933-42
references: 23932548
references: Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):408-13
references: 20452134